Stock News & Analysis

These two projects are big and innovative twists on concepts that previously existed in crypto.

Microsoft, Palantir, and Marvell all got upgrades last week -- but Marvell is the one I'd pick.

Morgan Stanley is projecting a $5 trillion valuation for the humanoid robots industry. These stocks are poised to thrive because of it.

Pharmaceutical stocks have been one of the best places to invest over the past year. Choosing between these two funds is really a question about how you want to own what comes next.

This under-the-radar financial stock boasts a Superscore of 75 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.

The stock is within 2% of its record close. Is cloud growth in the mid-40s enough to send it past?

One fund calls itself global but keeps over half its money in the U.S. The other goes fully international at a fifth of the cost.

IonQ stock is down 12% on the year, but could a turnaround be in the works?

One fund yields more and costs less. The other has held up better through every tough stretch. Here is how to choose.

This under-the-radar AI chipmaker just landed a multi-year OpenAI deal, and investors are taking notice.

IBB has delivered stronger returns than IYH but with dramatically sharper swings in both directions. Here is how to decide which trade-off fits your portfolio.

Microsoft stands out as a strong five-year hold because of its growing Azure and AI businesses, massive cash generation, and diversified business.

This under-the-radar renewable energy stock boasts a Superscore of 77 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.

Physical silver offers lower costs and no dividend, while gold miners provide equity diversification and income. Which metals strategy fits your portfolio?

The memory chipmaker still has plenty of irons in the fire.

Income investors can have more of what they want -- and less of what they don't.

VanEck offers lower costs and higher dividends with a concentrated pharma focus, while Simplify provides broader healthcare exposure and donates profits to breast cancer research.

OpenAI is a key player in the AI space.

One offers broad diversification at 0.08% cost, while the other targets concentrated biotech growth with higher volatility.

The chipmaker has had a great year, but its stock has risen too far, too fast.